David Alain Wohl, M.D., is a professor of medicine in the Division of Infectious Diseases at the University of North Carolina (UNC). He is site leader of the UNC AIDS Clinical Trials Unit at Chapel Hill, director of the North Carolina AIDS Education and Training Center (AETC), and co-director of HIV services for the North Carolina state prison system. In 2014, he became co-director of the UNC-Duke Clinical RM Ebola Response Consortium.
Dr. Wohl's research aims to optimize the treatment of HIV, including identifying the most effective therapeutic approaches and minimizing the adverse effects of therapy. He is also active in investigations focused on populations vulnerable to HIV, such as the incarcerated. He is active within the U.S. AIDS Clinical Trials Group and HIV Prevention Trials Network and served two terms as a member of the U.S. Department of Health and Human Services Antiretroviral Guidelines Panel.
As part of the response to the 2013-2016 Ebola outbreak in West Africa, Dr. Wohl led UNC clinical research efforts to test interventions for Ebola Virus Disease in Liberia and now directs a clinical cohort of Ebola survivors.
In addition to his research and administrative activities, Dr. Wohl maintains a large HIV continuity clinic at UNC.
Dr. Wohl has attended advisory boards for Abbott Laboratories, Tibotec, Janssen Pharmaceuticals, ViiV Healthcare, and Gilead Sciences. In addition, his university has received support for his research from Gilead Sciences and ViiV Healthcare. These disclosures were last updated on November 17, 2017.
Categories Covered:HIV Risks and Symptoms, HIV Testing, HIV Prevention and Transmission, Curing HIV, HIV Treatment and Medical Care, Physical Health Issues, HIV/AIDS Basics, Conceiving and Having a Baby, Non-HIV Sexually Transmitted Infections, Starting HIV Treatment and Medical Care, Switching or Stopping HIV Treatment, Disclosing Your HIV Status, History of HIV/AIDS, HIV Prevention for People With HIV, PEP (HIV Post-Exposure Prophylaxis), HIV/AIDS Statistics, People Over 50, Managing HIV Drug Resistance, HIV Drugs In Development, Understanding HIV-Related Lab Tests, Bone Problems and HIV, Financial Issues
An online calculator known as FRAX is one of the most highly regarded tools clinicians use to gauge a person's risk for breaking a bone. But as David Wohl, M.D., explains, it may not be super-accurate for people with HIV.
"This is one article on aging and HIV that will challenge the concept of people living with HIV having an early expiration date," writes David Alain Wohl, M.D.
Dr. David Wohl says recent data on ARV adherence isn't a license to play footloose with HIV meds. "But we need not freak out about missed doses here and missed doses there," he explains in this new HIV Research Takeaway.
Super-sensitive HIV tests are great, but what does it mean when they find that someone has a really low level of virus -- say, 150 copies or 50 copies?
I recently found out my daughter's father is a latent stage of aids. We had unprotected sex for years. I had his child and obviously tested during pregnancy and after childbirth as that is the norm where i live. Was negative and now after finding out...
Hello and thank you for taking time out to answer all of our questions. I am a healthy female that has been undetectable for 5 years and I am currently engaged to wonderful guy that I've been dating for almost 3 years. We are currently not using prot...
ibank Philippines Hello! I work in a busy clinical laboratory but I do paper works. We'll one time, I went inside the area where the technologists are processing some specimen. I was looking for a pen at that point when I saw one and just grabbed it ...
I had tested negative thrice in unigold and determine,Elisa,SD Bioline 3.0 antibody test(3,5.5 and 6.5 months) after condom protected sex with a female csw.Now I'm having shortness of breath,caugh,loose stool,recurrent mouth ulcer and swollen cervica...